
School of Medicine alumnus develops new sickle cell disease treatment
A new medication to treat symptoms of sickle cell disease, developed following 25 years of research by a Loma Linda University School of Medicine alumnus, has received approval from the U.S. Food and Drug Administration, the first new drug for the condition to receive FDA approval in nearly 20 years.
According to Yutaka Niihara, MD, MPH (SM ‘86), the new drug, known as Endari, significantly reduces the symptoms experienced by people with sickle cell disease.